MedTrace Logo

Topiramate and Cerebrovascular Response in Migraineurs

NCT02424318 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2015-04-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of topiramate on cerebrovascular reactivity and mean flow velocity to photic stimulation in migraineurs.

Conditions

  • Migraine Disorders

Interventions

DRUG

Topiramate

topiramate 25mg twice 1 week -\> topiramate 50mg twice 7 weeks

Sponsors & Collaborators

  • SMG-SNU Boramae Medical Center

    lead OTHER

Principal Investigators

  • Hyunwoo Nam, MD, PhD · SMG-SNU Boramae Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2009-12-31
Completion
2010-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02424318 on ClinicalTrials.gov